Summary
This study investigated the role of red blood cell distribution width (RDW) as a risk factor for hospital mortality in COVID-19 patients at a public hospital in Minas Gerais, Brazil. The study included 161 patients over 16 years old hospitalized between May and October 2020, with 39 (24.2%) deaths. Key mortality risk factors identified were age over 70 years (RR=2.78; p<0.001), male sex (RR=2.28; p=0.005), cardiovascular disease (RR=1.8; p=0.044), and abnormal chest X-ray upon admission (RR=3.07; p=0.022). Although high RDW at admission did not significantly predict mortality (31.1% vs 21.7%; RR=1.43; p=0.413), it was linked to higher mortality in patients aged 70 and over (66.7% vs 33.3%; RR=2; p=0.029). High RDW during hospitalization was a strong mortality factor for the entire cohort (41.1% vs 10.2%; RR=4.03; p<0.001) and at any time during the stay (39.7% vs 9.6%; RR=4.14; p<0.001). The Cox model analysis showed that age >70 years (HR=4.8; p<0.001), white race (HR=3.2; p=0.018), need for invasive ventilation (HR=3.8; p=0.001), and abnormal chest X-ray (HR=3.5; p=0.044) were significant risk factors, but RDW was not associated with mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted in accordance with the ethical principles established in the Declaration of Helsinki. The study protocol was reviewed and approved by the Institutional Review Board of UFMG, under the approval number 30437020.9.3001.5124. All participants were informed about the study's objectives, procedures, potential risks, and benefits, and they signed a written informed consent form prior to participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations and acronyms used in the manuscript
- COVID-19
- Coronavirus Disease 2019
- CT
- computed tomography
- HC-UFMG
- Hospital das Clínicas of the Universidade Federal de Minas Gerais
- HR
- Hazard Ratio
- ICU
- Intensive Care Unit
- MCV
- mean corpuscular volume
- MV
- mechanical ventilation
- PNAD
- National Household Sample Survey, in Portuguese: Pesquisa Nacional por Amostra de Domicílios
- PTE/DVT
- thromboembolism/deep venous thrombosis
- RDW
- Red blood cell distribution width
- RR
- Risk Ratio
- RT-PCR
- real-time polymerase chain reaction
- SARS
- Severe Acute Respiratory Syndrome
- SD
- standard deviation
- SUS
- Brazilian Unified Health System
